Member Posts > Cardiol Therapeutics Unveils Groundbreaking Research on Cannabidiol's Cardioprotective Effects
Cardiol Therapeutics Inc. has released a pivotal study in JACC: Basic to Translational Science, highlighting the potential of cannabidiol (CBD) in combating heart failure with preserved ejection fraction (HFpEF). Conducted in collaboration with Tecnológico de Monterrey and the DeBakey Heart and Vascular Center, the research underscores how CBD preserves mitochondrial function, reduces fibrosis, and improves calcium handling-key factors in cardiac health.
Key Takeaways for the Medical Community:
• CBD helps prevent heart remodeling and dysfunction in heart failure models.
• Mitochondrial stability and inflammation reduction play critical roles in therapeutic outcomes.
• CRD-38, Cardiol's proprietary formulation, is moving closer to clinical trials.
Dr. Andrew Hamer, Cardiol's Chief Medical Officer, emphasized that these findings will drive the next phase of CRD-38's clinical development.

#CardiolTherapeutics #InvestorRelations #StockMarket #HealthcareInvestments #BiotechStocks #Pharmaceuticals #CardiacCare #FinancialUpdates #HeartHealth #MedicalInnovation #Pericarditis #HealthcareResearch #AdvancedTherapies #CardiolRx #CRD38 #Myocarditis